US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cadrenal Therapeutics, Inc.

11.24

-0.2000-1.75%

Post-market: 11.00-0.2400-2.14%19:45 EDT

Volume:46.06K

Turnover:497.48K

Market Cap:22.11M

PE:-1.24

High:11.44

Open:11.14

Low:10.00

Close:11.44

Loading ...

Overview Company News Filings

Cadrenal Therapeutics Announces Promising Findings on Tecarfarin as Alternative Anticoagulant for LVAD Patients

Cadrenal Therapeutics Inc. to Engage Potential Partners at Upcoming BIO International Convention

Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

THOMSON REUTERS

Cadrenal Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Cadrenal Therapeutics Inc Qtrly Shr Loss $2.09

THOMSON REUTERS

Press Release: Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics Inc expected to post a loss of $1.64 a share - Earnings Preview

BRIEF-Cadrenal Therapeutics Inc - Files Prospectus Supplement For $2.17 Million ATM Offering

Cadrenal Therapeutics Inc - Files Prospectus Supplement for $2.17 Mln Atm Offering - SEC Filing

THOMSON REUTERS

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

CVKD: Preparing for Phase 3 Trial of Tecarfarin…

Zacks Small Cap Research

Noble Financial Remains a Buy on Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics FY 2024 GAAP EPS $(8.73) Misses $(7.59) Estimate

Press Release: Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial…

Zacks Small Cap Research

Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug

MT Newswires Live

BRIEF-Cadrenal Therapeutics Announces Collaboration Agreement With Abbott

Cadrenal Therapeutics Inc - Abbott to Share Insights From Heartmate 3 Trials

THOMSON REUTERS

Cadrenal Therapeutics Announces Collaboration Agreement With Abbott in Support of Pivotal Study of Tecarfarin in Patients With Heartmate 3™ Lvad

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CVKD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CVKD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CVKD\",,,,,undefined,":{"symbol":"CVKD","market":"US","secType":"STK","nameCN":"Cadrenal Therapeutics, Inc.","latestPrice":11.24,"timestamp":1750795200000,"preClose":11.44,"halted":0,"volume":46062,"hourTrading":{"tag":"盘后","latestPrice":11,"preClose":11.24,"latestTime":"19:45 EDT","volume":289,"amount":3176.13,"timestamp":1750808752336},"delay":0,"floatShares":1389732,"shares":1966675,"eps":-9.077537,"marketStatus":"Not Yet Opened","change":-0.2,"latestTime":"06-24 16:00:00 EDT","open":11.14,"high":11.44,"low":10,"amount":497483.833158,"amplitude":0.125874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-9.077537,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750838400000},"marketStatusCode":0,"adr":0,"listingDate":1674190800000,"exchange":"NASDAQ","adjPreClose":11.44,"preHourTrading":{"tag":"盘前","latestPrice":11.3,"preClose":11.44,"latestTime":"09:02 EDT","volume":13,"amount":146.030001,"timestamp":1750770153424},"postHourTrading":{"tag":"盘后","latestPrice":11,"preClose":11.24,"latestTime":"19:45 EDT","volume":289,"amount":3176.13,"timestamp":1750808752336},"volumeRatio":2.934035},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CVKD\",,,,,undefined,":{"symbol":"CVKD","floatShares":1389732,"roa":"-109.43%","roe":"-208.59%","lyrEps":-8.733851,"volumeRatio":2.934035,"shares":1966675,"dividePrice":0,"high":11.44,"amplitude":0.125874,"preClose":11.44,"low":10,"week52Low":5.7,"pbRate":"3.62","week52High":22.9011,"institutionHeld":0,"latestPrice":11.24,"eps":-9.077537,"divideRate":0,"volume":46062,"delay":0,"ttmEps":-9.077537,"open":11.14,"prevYearClose":14.49,"prevWeekClose":12.35,"prevMonthClose":13.33,"prevQuarterClose":17.63,"fiveDayClose":13.7,"twentyDayClose":14.75,"sixtyDayClose":18.71},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CVKD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542519917","title":"Cadrenal Therapeutics Announces Promising Findings on Tecarfarin as Alternative Anticoagulant for LVAD Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2542519917","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542519917?lang=en_us&edition=fundamental","pubTime":"2025-06-12 20:01","pubTimestamp":1749729712,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics Inc. , a biopharmaceutical company focused on developing novel therapeutics for cardiovascular diseases, has announced new findings from a third-party research study conducted by Guidehouse. The study highlights the economic and medical burdens faced by patients with left ventricular assist devices  who require chronic oral anticoagulation. It identifies tecarfarin, a Phase 3-ready oral anticoagulant under development by Cadrenal, as a potential alternative to warfarin. Tecarfarin is noted for its unique metabolic pathway, which may provide more consistent anticoagulation control and reduce the risk of drug interactions and adverse events. The research findings emphasize the significant clinical and economic impact of major bleeding events in this patient population, with hospitalization costs averaging $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds. The results have already been presented.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL5b7c19:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"gpt_icon":0},{"id":"2540632680","title":"Cadrenal Therapeutics Inc. to Engage Potential Partners at Upcoming BIO International Convention","url":"https://stock-news.laohu8.com/highlight/detail?id=2540632680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540632680?lang=en_us&edition=fundamental","pubTime":"2025-06-04 20:00","pubTimestamp":1749038442,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics Inc. will attend the BIO International Convention 2025, which takes place from June 16-19 in Boston. The company's executive leadership team will engage in one-on-one meetings with investors and potential partners to discuss the strategic direction and clinical development of its lead asset, tecarfarin.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL57XP4W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"gpt_icon":0},{"id":"2535936035","title":"Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2535936035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535936035?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:18","pubTimestamp":1747390732,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report), with a price target of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-cadrenal-therapeutics-inc-amid-strategic-developments-and-fda-trial-milestone?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-cadrenal-therapeutics-inc-amid-strategic-developments-and-fda-trial-milestone?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CVKD"],"gpt_icon":0},{"id":"2535769849","title":"Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2535769849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535769849?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:30","pubTimestamp":1747308600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUA3L78VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVKD","BK4007"],"gpt_icon":0},{"id":"2534653674","title":"Cadrenal Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534653674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534653674?lang=en_us&edition=fundamental","pubTime":"2025-05-10 05:01","pubTimestamp":1746824489,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryCadrenal Therapeutics Inc CVKD.OQ reported a quarterly adjusted loss of $2.09 per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH3DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD"],"gpt_icon":0},{"id":"2533817051","title":"Cadrenal Therapeutics Inc Qtrly Shr Loss $2.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2533817051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533817051?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:03","pubTimestamp":1746705839,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1OY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CVKD"],"gpt_icon":0},{"id":"2533810301","title":"Press Release: Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533810301","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533810301?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:00","pubTimestamp":1746705600,"startTime":"0","endTime":"0","summary":"FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin. Collaboration Agreement with Abbott  validates the need for new anticoagulation options. Cadrenal Therapeutics, Inc. , a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin.\"In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024,\" said Quang X. Pham, Chairman & CEO. \"The appointment of James Ferguson, M.D., FACC, FAHA, as our Chief Medical Officer positions us for success in reviewing potential assets to add to our portfolio and designing and executing our clinical program for tecarfarin. The finalized Collaboration Agreement with Abbott validates the critical need in the market for a new anticoagulant for patients with left v","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","SG9999002232.USD","CVKD","IE00B4R5TH58.HKD","API","LENZ","BK4585","LU1989763427.SGD","ABT","LU0122379950.USD","LU0266013472.USD","TM","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4604","ODD","LU0234572021.USD","BK4535","BK4082","BK4099","BK4555","LU2112291526.USD","IE00B2B36J28.USD","SG9999002224.SGD","LU2133065610.SGD","BK4023","LU1914381329.SGD","BK4551","BK4503","SGXZ23171101.USD","BK4566","LU1023059063.AUD","LU2468319806.SGD","BK4588","LU0868494617.USD","BK4592","03160","BK4504","IE0009355771.USD","IE00BJT1NW94.SGD","LU2089984988.USD","LU2237957811.SGD","BK4581","LU0170899867.USD","BK4568","LU1989763690.USD","BK4139","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1721429741.USD"],"gpt_icon":0},{"id":"2533966307","title":"Cadrenal Therapeutics Inc  expected to post a loss of $1.64 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533966307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533966307?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:02","pubTimestamp":1746648163,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics Inc  expected to post a loss of $1.64 a share - Earnings Preview Cadrenal Therapeutics Inc CVKD.OQ CVKD.O is expected to show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL8N3RF31D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD"],"gpt_icon":0},{"id":"2528975791","title":"BRIEF-Cadrenal Therapeutics Inc - Files Prospectus Supplement For $2.17 Million ATM Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2528975791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528975791?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:16","pubTimestamp":1744885014,"startTime":"0","endTime":"0","summary":"BRIEF-Cadrenal Therapeutics Inc - Files Prospectus Supplement For $2.17 Million ATM OfferingApril 17  - Cadrenal Therapeutics Inc CVKD.O:CADRENAL THERAPEUTICS INC - FILES PROSPECTUS SUPPLEMENT FOR $2.17 MILLION ATM OFFERING - SEC FILINGFurther company coverage: CVKD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV19F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"gpt_icon":0},{"id":"2528919547","title":"Cadrenal Therapeutics Inc - Files Prospectus Supplement for $2.17 Mln Atm Offering - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2528919547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528919547?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:12","pubTimestamp":1744884772,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV19F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CVKD"],"gpt_icon":0},{"id":"2524025521","title":"Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524025521","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524025521?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"PONTE VEDRA, Fla., April 03, 2025----Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company’s commitment to advancing innovation and clinical development in anticoagulation therapy.Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and key opinion leaders in anticoagulation therapy.Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit www.cadrenal.com and connect with us on LinkedIn.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cadrenal-therapeutics-participates-key-medical-120000485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","BK4183","LENZ","CVKD","ODD"],"gpt_icon":0},{"id":"2524974387","title":"CVKD: Preparing for Phase 3 Trial of Tecarfarin…","url":"https://stock-news.laohu8.com/highlight/detail?id=2524974387","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524974387?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:24","pubTimestamp":1743431040,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics, Inc.  is a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant intended to prevent heart attacks, stroke, and death due to blood clots in patients suffering from rare cardiovascular conditions requiring chronic anticoagulation. These conditions include patients with left ventricular assist devices , patients with end-stage kidney disease  and atrial fibrillation , and patients with mechanical heart valves with difficult-to-control time in therapeutic range .The company is currently preparing for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices  trial. Recently, Cardrenal announced a collaboration agreement with Abbott in which Abbott will assist Cadrenal with trial design, site identification, trial awareness, and HeartMate 3 expertise. Abbott is the maker of the HeartMate 3 LVAD, which is the only LVAD currently approved in the U.S.As of December 31, 2024, Cadrenal","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvkd-preparing-phase-3-trial-142400100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU1061106388.HKD","ODD","LU1691799644.USD","LU1989763690.USD","IE0002141913.USD","LU2133065610.SGD","LU2089984988.USD","BK4566","IE00B2B36J28.USD","LU1023059063.AUD","SG9999002224.SGD","SGXZ23171101.USD","LU0170899867.USD","LU0868494617.USD","LU1914381329.SGD","IE00BJJMRZ35.SGD","LU2237957811.SGD","LU1721429402.USD","IE00B4R5TH58.HKD","BK4585","SG9999002232.USD","LU0122379950.USD","BK4504","LU2112291526.USD","LU2237957902.USD","BK4592","BK4082","CVKD","SG9999004303.SGD","BK4139","LU0234572021.USD","LU1721429741.USD","BK4007","LU0266013472.USD","BK4183","LU2468319806.SGD","IE0009355771.USD","LU1057294990.SGD","LU1989763427.SGD","BK4533","ABT","BK4581","CDMO","BK4588"],"gpt_icon":0},{"id":"2519080795","title":"Noble Financial Remains a Buy on Cadrenal Therapeutics, Inc. (CVKD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2519080795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519080795?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:35","pubTimestamp":1741959328,"startTime":"0","endTime":"0","summary":"Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report) today and set a price target...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-remains-a-buy-on-cadrenal-therapeutics-inc-cvkd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-remains-a-buy-on-cadrenal-therapeutics-inc-cvkd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVKD","NBL","BK4007"],"gpt_icon":0},{"id":"2519690288","title":"Cadrenal Therapeutics FY 2024 GAAP EPS $(8.73) Misses $(7.59) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2519690288","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519690288?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:21","pubTimestamp":1741897286,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(8.73) per share which missed the analyst consensus estimate of $(7.59) by 15.02 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44316382/cadrenal-therapeutics-fy-2024-gaap-eps-8-73-misses-7-59-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","LENZ"],"gpt_icon":0},{"id":"2519695478","title":"Press Release: Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin","url":"https://stock-news.laohu8.com/highlight/detail?id=2519695478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519695478?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:05","pubTimestamp":1741896300,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin. Recent Collaboration Agreement with Abbott Global Enterprises Limited  in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD. Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin. Cadrenal Therapeutics, Inc. , a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin.Full Year 2024 Key Accomplishments and Recent Highlights. Cadrenal appointed James J. Ferguson, MD, FACC, FAHA, as Chief Medical Officer to lead the late-stage clinical development of tecarfarin and other indications in rare cardiovascular conditions requiring life-long anticoagulation the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","SGXZ23171101.USD","IE0009355771.USD","IE0002141913.USD","LU0170899867.USD","LU0122379950.USD","SG9999002232.USD","SG9999004303.SGD","BK4183","IE00B4R5TH58.HKD","LU1061106388.HKD","LU2112291526.USD","BK4592","IE00BJT1NW94.SGD","LU1691799644.USD","LU1914381329.SGD","BK4588","LU1989763427.SGD","LENZ","ABT","CVKD","IE00B2B36J28.USD","LU2089984988.USD","LU2468319806.SGD","BK4139","BK4082","BK4566","LU1989763690.USD","BK4504","LU1057294990.SGD","LU1721429402.USD","BK4585","LU2237957811.SGD","LU0868494617.USD","FORD","IE00BJJMRZ35.SGD","BK4533","LU2237957902.USD","SG9999002224.SGD","ODD","LU1721429741.USD","03160","CDMO","TM","LU2133065610.SGD","BK4007","LU0234572021.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","BK4604"],"gpt_icon":0},{"id":"2517452987","title":"CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial…","url":"https://stock-news.laohu8.com/highlight/detail?id=2517452987","media":"Zacks Small Cap Research","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517452987?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:15","pubTimestamp":1741353300,"startTime":"0","endTime":"0","summary":"Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial. On March 4, 2025, Cadrenal Therapeutics, Inc.  announced a collaboration agreement with Abbott for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices  trial. In August 2024, Cadrenal had announced it was in discussions with Abbott about the pivotal Phase 3 trial of tecarfarin for patients with LVADs, and this agreement between the two companies is the result of those discussions. Specifically, the agreement calls for Abbott to assist Cadrenal with trial design, site identification, trial awareness, and HeartMate 3 expertise. Abbott is the maker of the HeartMate 3 LVAD, which is the only LVAD currently approved in the U.S.Having Abbott assist with many different facets of the Phase 3 TECH-LVAD trial is going to be a huge advantage for Cadrenal as Abbott has a wealth of experience with LVAD patients. The agreement will allow Cadrenal to utilize Abbott’s network of trial sites a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvkd-collaborating-abbott-pivotal-phase-131500611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABT","CVKD"],"gpt_icon":0},{"id":"2516679026","title":"Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516679026","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516679026?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:47","pubTimestamp":1741096056,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics  said Tuesday it has signed a collaboration agreement with Abbott  to support a trial of its tecarfarin anticoagulation and hemocompatibility with left ventricular assist devices.Financial terms were not disclosed.Under the terms of the agreement, Abbott will support Cadrenal on the planning and execution of the trial to evaluate the efficacy and safety of tecarfarin in patients with left ventricular assist devices.Abbott will also share insights from recent trials and will support Cadrenal with trial design, site identification, trial awareness, and expertise.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1691799644.USD","LU2237957811.SGD","LU2237957902.USD","LU1061106388.HKD","LU0122379950.USD","SGXZ23171101.USD","CVKD","IE00B4R5TH58.HKD","BK4504","BK4581","BK4082","BK4568","LU2112291526.USD","BK4566","LU1023059063.AUD","BK4007","BK4585","LU1914381329.SGD","ABT.AU","SG9999002232.USD","BK4588","LU1989763690.USD","LU2133065610.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU1721429741.USD","LU0266013472.USD","IE0009355771.USD","LU2468319806.SGD","BK4533","LU0868494617.USD","LU0170899867.USD","SG9999002224.SGD","IE00BFTCPJ56.SGD","LU1721429402.USD","SG9999004303.SGD","LU2089984988.USD","LU1057294990.SGD","BK4139","LU1989763427.SGD","IE00BJJMRZ35.SGD","BK4592","LU0234572021.USD","IE0002141913.USD","ABT","LENZ"],"gpt_icon":0},{"id":"2516167696","title":"BRIEF-Cadrenal Therapeutics Announces Collaboration Agreement With Abbott","url":"https://stock-news.laohu8.com/highlight/detail?id=2516167696","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516167696?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:14","pubTimestamp":1741094067,"startTime":"0","endTime":"0","summary":"BRIEF-Cadrenal Therapeutics Announces Collaboration Agreement With Abbott March 4 (Reuters) - Cadrenal Therapeutics Inc CVKD.O:CADRENAL THERAPEUTICS ANNOUNCES COLLABORATION AGREEMENT WITH ABBOTT IN SU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA76BCYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU1057294990.SGD","BK4568","LU1989763690.USD","LU1691799644.USD","BK4581","LU0170899867.USD","CVKD","BK4585","LU1914381329.SGD","LU1023059063.AUD","LU1061106388.HKD","IE00BJT1NW94.SGD","BK4007","LU2133065610.SGD","LU2112291526.USD","BK4566","LU0234572021.USD","ABT","IE00B4R5TH58.HKD","SG9999002224.SGD","LU0868494617.USD","IE00B2B36J28.USD","LU2237957902.USD","IE00BFTCPJ56.SGD","LU0122379950.USD","IE0002141913.USD","SG9999002232.USD","LU2237957811.SGD","BK4592","LU1721429402.USD","IE0009355771.USD","BK4082","BK4533","IE00BJJMRZ35.SGD","BK4588","LU1989763427.SGD","LU0266013472.USD","LU2468319806.SGD","SGXZ23171101.USD","LU1721429741.USD","LU2089984988.USD","SG9999004303.SGD"],"gpt_icon":0},{"id":"2516754306","title":"Cadrenal Therapeutics Inc - Abbott to Share Insights From Heartmate 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516754306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516754306?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA76BCYD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU1061106388.HKD","LU1691799644.USD","LU1989763690.USD","IE0002141913.USD","LU2133065610.SGD","LU2089984988.USD","BK4566","IE00B2B36J28.USD","LU1023059063.AUD","SG9999002224.SGD","SGXZ23171101.USD","LU0170899867.USD","LU0868494617.USD","LU1914381329.SGD","IE00BJJMRZ35.SGD","LU2237957811.SGD","LU1721429402.USD","IE00B4R5TH58.HKD","BK4585","SG9999002232.USD","LU0122379950.USD","BK4504","LU2112291526.USD","LU2237957902.USD","BK4592","BK4082","CVKD","SG9999004303.SGD","LU0234572021.USD","LU1721429741.USD","BK4007","LU0266013472.USD","LU2468319806.SGD","IE0009355771.USD","LU1057294990.SGD","LU1989763427.SGD","BK4533","ABT","BK4581","BK4588"],"gpt_icon":0},{"id":"2516675127","title":"Cadrenal Therapeutics Announces Collaboration Agreement With Abbott in Support of Pivotal Study of Tecarfarin in Patients With Heartmate 3™ Lvad","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675127?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA76BCYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVKD","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CVKD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"CVKD","fiscalQuarterEnding":"2025/03","expectedEps":-1.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-2.09},{"market":"US","date":"2024-08-20","symbol":"CVKD","defaultRemindTime":1724160600000,"type":"split","dateTimestamp":1724126400000,"forFactor":15,"toFactor":1,"ratio":15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CVKD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CVKD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1702958400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CVKD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CVKD","date":"2025-06-23","current":-1.892587,"percent":0.453913,"low":-6.5442,"twenty":-3.160912,"median":-1.547537,"eighty":-0.812493,"high":-0.416067,"avg":-1.9946,"sd":1.229176,"marketCap":24288436},"quantilePoints":[{"date":"2023-01-20","current":-6.5442,"twenty":-6.16384,"median":-5.593301,"eighty":-5.593301,"marketCap":47934449},{"date":"2023-01-27","current":-4.161603,"twenty":-5.973233,"median":-5.338088,"eighty":-4.549173,"marketCap":30482586},{"date":"2023-02-03","current":-3.812156,"twenty":-5.593301,"median":-4.511051,"eighty":-4.113951,"marketCap":27922980},{"date":"2023-02-10","current":-3.160912,"twenty":-5.38913,"median":-4.288675,"eighty":-3.488122,"marketCap":23152804},{"date":"2023-02-17","current":-3.573896,"twenty":-4.892266,"median":-4.082183,"eighty":-3.392818,"marketCap":26177793},{"date":"2023-02-24","current":-3.345166,"twenty":-4.587294,"median":-3.573896,"eighty":-3.380111,"marketCap":24502414},{"date":"2023-03-03","current":-2.875001,"twenty":-4.507652,"median":-3.569925,"eighty":-3.160912,"marketCap":21058580},{"date":"2023-03-10","current":-2.589089,"twenty":-4.478393,"median":-3.494476,"eighty":-3.058111,"marketCap":18964357},{"date":"2023-03-17","current":-2.271409,"twenty":-4.364918,"median":-3.399172,"eighty":-2.900415,"marketCap":16637442},{"date":"2023-03-24","current":-1.985498,"twenty":-4.145719,"median":-3.271465,"eighty":-2.525553,"marketCap":14543218},{"date":"2023-03-31","current":-2.239641,"twenty":-4.082183,"median":-3.15297,"eighty":-2.291105,"marketCap":16404750},{"date":"2023-04-06","current":-2.112569,"twenty":-4.082183,"median":-3.137086,"eighty":-2.249171,"marketCap":15473984},{"date":"2023-04-12","current":-2.229793,"twenty":-4.028178,"median":-3.11326,"eighty":-2.242818,"marketCap":16332616},{"date":"2023-04-21","current":-2.446133,"twenty":-3.866161,"median":-3.03114,"eighty":-2.237671,"marketCap":17917245},{"date":"2023-04-28","current":-2.366713,"twenty":-3.6692,"median":-2.946479,"eighty":-2.249171,"marketCap":17335516},{"date":"2023-05-05","current":-2.096686,"twenty":-3.573896,"median":-2.875001,"eighty":-2.188781,"marketCap":15357639},{"date":"2023-05-12","current":-1.444685,"twenty":-3.573896,"median":-2.612915,"eighty":-2.169752,"marketCap":17800899},{"date":"2023-05-19","current":-1.359704,"twenty":-3.569131,"median":-2.462017,"eighty":-2.077625,"marketCap":16753788},{"date":"2023-05-26","current":-1.284383,"twenty":-3.546035,"median":-2.446133,"eighty":-1.985498,"marketCap":15825717},{"date":"2023-06-02","current":-1.346224,"twenty":-3.517444,"median":-2.384186,"eighty":-1.928316,"marketCap":16587696},{"date":"2023-06-09","current":-1.503204,"twenty":-3.469062,"median":-2.334945,"eighty":-1.45944,"marketCap":18521951},{"date":"2023-06-16","current":-1.44612,"twenty":-3.43094,"median":-2.283322,"eighty":-1.45944,"marketCap":17818586},{"date":"2023-06-23","current":-1.484176,"twenty":-3.418233,"median":-2.263467,"eighty":-1.465148,"marketCap":18287496},{"date":"2023-06-30","current":-1.398551,"twenty":-3.367404,"median":-2.247583,"eighty":-1.465148,"marketCap":17232448},{"date":"2023-07-07","current":-1.417578,"twenty":-3.349614,"median":-2.226775,"eighty":-1.445833,"marketCap":17466903},{"date":"2023-07-14","current":-1.503299,"twenty":-3.286205,"median":-2.191989,"eighty":-1.443298,"marketCap":18523123},{"date":"2023-07-21","current":-1.637011,"twenty":-3.183023,"median":-2.150431,"eighty":-1.445833,"marketCap":20170670},{"date":"2023-07-28","current":-1.152922,"twenty":-3.160912,"median":-2.112569,"eighty":-1.436606,"marketCap":14205899},{"date":"2023-08-04","current":-1.14188,"twenty":-3.148205,"median":-2.045063,"eighty":-1.406161,"marketCap":14069843},{"date":"2023-08-11","current":-0.924489,"twenty":-3.132321,"median":-1.985498,"eighty":-1.379336,"marketCap":11854271},{"date":"2023-08-18","current":-0.791165,"twenty":-3.116437,"median":-1.961672,"eighty":-1.351057,"marketCap":10144725},{"date":"2023-08-25","current":-0.756633,"twenty":-3.058111,"median":-1.906237,"eighty":-1.33893,"marketCap":9701938},{"date":"2023-09-01","current":-0.782025,"twenty":-3.028503,"median":-1.714964,"eighty":-1.314525,"marketCap":10027520},{"date":"2023-09-08","current":-0.93325,"twenty":-2.992542,"median":-1.675857,"eighty":-1.277692,"marketCap":11966608},{"date":"2023-09-15","current":-0.791064,"twenty":-2.948067,"median":-1.596605,"eighty":-1.146297,"marketCap":10143423},{"date":"2023-09-22","current":-0.685541,"twenty":-2.919476,"median":-1.522232,"eighty":-1.104853,"marketCap":8790358},{"date":"2023-09-29","current":-0.680463,"twenty":-2.884531,"median":-1.503251,"eighty":-0.944749,"marketCap":8725245},{"date":"2023-10-06","current":-0.665229,"twenty":-2.792404,"median":-1.503204,"eighty":-0.904366,"marketCap":8529903},{"date":"2023-10-13","current":-0.649081,"twenty":-2.655802,"median":-1.479419,"eighty":-0.871399,"marketCap":8322842},{"date":"2023-10-20","current":-0.597183,"twenty":-2.61768,"median":-1.473616,"eighty":-0.791104,"marketCap":7657379},{"date":"2023-10-27","current":-0.503746,"twenty":-2.598619,"median":-1.465148,"eighty":-0.784463,"marketCap":6459285},{"date":"2023-11-03","current":-0.446871,"twenty":-2.525553,"median":-1.450877,"eighty":-0.769227,"marketCap":5730011},{"date":"2023-11-10","current":-0.446511,"twenty":-2.471547,"median":-1.444685,"eighty":-0.749525,"marketCap":5730011},{"date":"2023-11-17","current":-0.457674,"twenty":-2.462017,"median":-1.436606,"eighty":-0.722103,"marketCap":5873262},{"date":"2023-11-22","current":-0.507704,"twenty":-2.455663,"median":-1.417578,"eighty":-0.721088,"marketCap":6515283},{"date":"2023-12-01","current":-0.466807,"twenty":-2.446133,"median":-1.403307,"eighty":-0.699922,"marketCap":5990466},{"date":"2023-12-08","current":-0.471881,"twenty":-2.427072,"median":-1.388031,"eighty":-0.680463,"marketCap":6055580},{"date":"2023-12-15","current":-0.559052,"twenty":-2.387045,"median":-1.376708,"eighty":-0.648167,"marketCap":7174222},{"date":"2023-12-22","current":-0.56514,"twenty":-2.368619,"median":-1.351076,"eighty":-0.63015,"marketCap":7252358},{"date":"2023-12-29","current":-0.722638,"twenty":-2.366713,"median":-1.348603,"eighty":-0.629682,"marketCap":9273503},{"date":"2024-01-05","current":-0.635264,"twenty":-2.347652,"median":-1.341467,"eighty":-0.629743,"marketCap":8152244},{"date":"2024-01-12","current":-0.620651,"twenty":-2.315884,"median":-1.326907,"eighty":-0.629682,"marketCap":7964716},{"date":"2024-01-19","current":-0.953911,"twenty":-2.296823,"median":-1.312673,"eighty":-0.629723,"marketCap":12241388},{"date":"2024-01-26","current":-1.319238,"twenty":-2.284116,"median":-1.293897,"eighty":-0.63015,"marketCap":16929580},{"date":"2024-02-02","current":-1.430866,"twenty":-2.276174,"median":-1.320586,"eighty":-0.632524,"marketCap":18362083},{"date":"2024-02-09","current":-0.923467,"twenty":-2.265055,"median":-1.321934,"eighty":-0.637094,"marketCap":11850706},{"date":"2024-02-16","current":-0.791644,"twenty":-2.255525,"median":-1.298654,"eighty":-0.640854,"marketCap":10159050},{"date":"2024-02-23","current":-0.743847,"twenty":-2.252348,"median":-1.278807,"eighty":-0.643003,"marketCap":9545678},{"date":"2024-03-01","current":-0.714418,"twenty":-2.237671,"median":-1.221262,"eighty":-0.639426,"marketCap":9168018},{"date":"2024-03-08","current":-0.654241,"twenty":-2.228586,"median":-1.149822,"eighty":-0.640346,"marketCap":8395769},{"date":"2024-03-15","current":-1.139373,"twenty":-2.218452,"median":-1.14188,"eighty":-0.642618,"marketCap":9521837},{"date":"2024-03-22","current":-1.2068,"twenty":-2.196183,"median":-1.140626,"eighty":-0.643971,"marketCap":10085335},{"date":"2024-03-28","current":-1.225937,"twenty":-2.191989,"median":-1.148028,"eighty":-0.645513,"marketCap":10245260},{"date":"2024-04-05","current":-1.16485,"twenty":-2.176105,"median":-1.152922,"eighty":-0.647557,"marketCap":9734749},{"date":"2024-04-12","current":-0.835183,"twenty":-2.160222,"median":-1.146113,"eighty":-0.649081,"marketCap":6979692},{"date":"2024-04-19","current":-0.823306,"twenty":-2.140639,"median":-1.139373,"eighty":-0.654241,"marketCap":6880439},{"date":"2024-04-26","current":-0.81143,"twenty":-2.128453,"median":-1.124432,"eighty":-0.658604,"marketCap":6781187},{"date":"2024-05-03","current":-0.890734,"twenty":-2.112569,"median":-1.111003,"eighty":-0.664084,"marketCap":7443938},{"date":"2024-05-10","current":-0.929811,"twenty":-2.096686,"median":-1.0981,"eighty":-0.664287,"marketCap":7770510},{"date":"2024-05-17","current":-1.420575,"twenty":-2.049034,"median":-1.111003,"eighty":-0.665229,"marketCap":6885242},{"date":"2024-05-24","current":-1.383913,"twenty":-2.041092,"median":-1.124432,"eighty":-0.669767,"marketCap":6707548},{"date":"2024-05-31","current":-1.354187,"twenty":-2.034738,"median":-1.135559,"eighty":-0.672852,"marketCap":6563472},{"date":"2024-06-07","current":-1.651117,"twenty":-1.995028,"median":-1.145503,"eighty":-0.674597,"marketCap":8002633},{"date":"2024-06-14","current":-1.462522,"twenty":-1.985498,"median":-1.149334,"eighty":-0.676934,"marketCap":7088550},{"date":"2024-06-21","current":-1.516029,"twenty":-1.985498,"median":-1.156171,"eighty":-0.679183,"marketCap":7347887},{"date":"2024-06-28","current":-1.504138,"twenty":-1.985498,"median":-1.16485,"eighty":-0.680036,"marketCap":7290256},{"date":"2024-07-05","current":-1.592623,"twenty":-1.956907,"median":-1.185729,"eighty":-0.680463,"marketCap":7719123},{"date":"2024-07-12","current":-1.549057,"twenty":-1.928316,"median":-1.2068,"eighty":-0.68257,"marketCap":7507971},{"date":"2024-07-15","current":-1.520322,"twenty":-1.925139,"median":-1.2068,"eighty":-0.683272,"marketCap":7368698},{"date":"2024-08-02","current":-1.416942,"twenty":-1.921962,"median":-1.214031,"eighty":-0.683974,"marketCap":6867633},{"date":"2024-08-09","current":-1.111674,"twenty":-1.906237,"median":-1.225937,"eighty":-0.685541,"marketCap":6933267},{"date":"2024-08-16","current":-1.293659,"twenty":-1.846933,"median":-1.234183,"eighty":-0.690721,"marketCap":8068268},{"date":"2024-08-23","current":-1.172164,"twenty":-1.818901,"median":-1.225937,"eighty":-0.699354,"marketCap":7310532},{"date":"2024-08-30","current":-1.264569,"twenty":-1.714964,"median":-1.241521,"eighty":-0.700775,"marketCap":7886837},{"date":"2024-09-06","current":-1.377507,"twenty":-1.706882,"median":-1.245795,"eighty":-0.702272,"marketCap":8591209},{"date":"2024-09-13","current":-1.830972,"twenty":-1.706882,"median":-1.246644,"eighty":-0.711712,"marketCap":11419371},{"date":"2024-09-20","current":-1.918243,"twenty":-1.834164,"median":-1.261146,"eighty":-0.71433,"marketCap":11963659},{"date":"2024-09-27","current":-2.482935,"twenty":-1.908638,"median":-1.273231,"eighty":-0.715692,"marketCap":15485521},{"date":"2024-10-04","current":-1.950755,"twenty":-1.957258,"median":-1.289021,"eighty":-0.720072,"marketCap":12166433},{"date":"2024-10-11","current":-1.928578,"twenty":-1.985498,"median":-1.30307,"eighty":-0.721088,"marketCap":12028120},{"date":"2024-10-18","current":-2.789238,"twenty":-2.037954,"median":-1.318426,"eighty":-0.721575,"marketCap":17395865},{"date":"2024-10-25","current":-2.86453,"twenty":-2.049228,"median":-1.322439,"eighty":-0.722103,"marketCap":17865446},{"date":"2024-10-31","current":-3.933452,"twenty":-2.070731,"median":-1.331376,"eighty":-0.722465,"marketCap":24532076},{"date":"2024-11-08","current":-3.909452,"twenty":-2.133327,"median":-1.338437,"eighty":-0.727802,"marketCap":24382399},{"date":"2024-11-15","current":-3.259855,"twenty":-2.194086,"median":-1.341467,"eighty":-0.734352,"marketCap":24801495},{"date":"2024-11-22","current":-3.282348,"twenty":-2.233732,"median":-1.351028,"eighty":-0.73941,"marketCap":24972628},{"date":"2024-11-29","current":-3.558806,"twenty":-2.265055,"median":-1.353013,"eighty":-0.74173,"marketCap":27075962},{"date":"2024-12-06","current":-3.132405,"twenty":-2.307334,"median":-1.357489,"eighty":-0.742873,"marketCap":23831837},{"date":"2024-12-13","current":-2.717719,"twenty":-2.368619,"median":-1.360113,"eighty":-0.745058,"marketCap":20676837},{"date":"2024-12-20","current":-3.394806,"twenty":-2.438951,"median":-1.363105,"eighty":-0.747693,"marketCap":25828222},{"date":"2024-12-27","current":-3.854006,"twenty":-2.462017,"median":-1.369978,"eighty":-0.749448,"marketCap":29321894},{"date":"2025-01-03","current":-3.631435,"twenty":-2.481224,"median":-1.377507,"eighty":-0.751556,"marketCap":27628533},{"date":"2025-01-10","current":-3.877435,"twenty":-2.523165,"median":-1.379523,"eighty":-0.753182,"marketCap":29500143},{"date":"2025-01-17","current":-4.264007,"twenty":-2.624538,"median":-1.387215,"eighty":-0.756024,"marketCap":32441245},{"date":"2025-01-24","current":-4.636522,"twenty":-2.674136,"median":-1.387903,"eighty":-0.758704,"marketCap":35275397},{"date":"2025-01-31","current":-4.458465,"twenty":-2.840559,"median":-1.398551,"eighty":-0.76167,"marketCap":33920708},{"date":"2025-02-07","current":-4.474865,"twenty":-2.909946,"median":-1.409317,"eighty":-0.766663,"marketCap":34045482},{"date":"2025-02-14","current":-4.49595,"twenty":-2.953876,"median":-1.417578,"eighty":-0.770226,"marketCap":34205906},{"date":"2025-02-21","current":-4.50415,"twenty":-3.001398,"median":-1.420575,"eighty":-0.772831,"marketCap":34268293},{"date":"2025-02-28","current":-4.313207,"twenty":-3.066784,"median":-1.427287,"eighty":-0.777478,"marketCap":32815567},{"date":"2025-03-07","current":-3.912578,"twenty":-3.139979,"median":-1.436606,"eighty":-0.780079,"marketCap":29767516},{"date":"2025-03-14","current":-4.088293,"twenty":-3.197171,"median":-1.445403,"eighty":-0.780934,"marketCap":31104380},{"date":"2025-03-21","current":-3.441281,"twenty":-3.248668,"median":-1.453604,"eighty":-0.782025,"marketCap":36654345},{"date":"2025-03-28","current":-3.301865,"twenty":-3.277995,"median":-1.456931,"eighty":-0.78237,"marketCap":35169374},{"date":"2025-04-04","current":-2.968325,"twenty":-3.266821,"median":-1.464503,"eighty":-0.783762,"marketCap":31616722},{"date":"2025-04-11","current":-2.518311,"twenty":-3.259068,"median":-1.469382,"eighty":-0.787263,"marketCap":26823461},{"date":"2025-04-17","current":-2.85891,"twenty":-3.257859,"median":-1.474662,"eighty":-0.790653,"marketCap":30451302},{"date":"2025-04-25","current":-3.000091,"twenty":-3.257392,"median":-1.49369,"eighty":-0.791084,"marketCap":31955070},{"date":"2025-05-02","current":-2.911853,"twenty":-3.251752,"median":-1.503204,"eighty":-0.791261,"marketCap":31015215},{"date":"2025-05-09","current":-2.270277,"twenty":-3.230283,"median":-1.504138,"eighty":-0.792361,"marketCap":29135505},{"date":"2025-05-16","current":-2.217562,"twenty":-3.211785,"median":-1.51768,"eighty":-0.795364,"marketCap":28458997},{"date":"2025-05-23","current":-2.303286,"twenty":-3.207473,"median":-1.520322,"eighty":-0.798283,"marketCap":29559125},{"date":"2025-05-30","current":-2.048131,"twenty":-3.194675,"median":-1.522232,"eighty":-0.80779,"marketCap":26284611},{"date":"2025-06-06","current":-2.238922,"twenty":-3.17692,"median":-1.535185,"eighty":-0.81143,"marketCap":28733121},{"date":"2025-06-13","current":-2.297156,"twenty":-3.160912,"median":-1.541956,"eighty":-0.811839,"marketCap":29480458},{"date":"2025-06-20","current":-2.051962,"twenty":-3.160912,"median":-1.546017,"eighty":-0.812362,"marketCap":26333778},{"date":"2025-06-23","current":-1.892587,"twenty":-3.160912,"median":-1.547537,"eighty":-0.812493,"marketCap":24288436}],"updateTime":1750803115116}}}